Researchers in the cancer nanomedicine community
debate whether use of tiny structures, called nanoparticles, can
best deliver drug therapy to tumors passively—allowing the
nanoparticles to diffuse into tumors and become held in place, or
actively—adding a targeted anti-cancer molecule to bind to specific
cancer cell receptors and, in theory, keep the nanoparticle in the
tumor longer. Now, new research on human and mouse tumors in mice
by investigators at the Johns Hopkins Kimmel Cancer Center suggests
the question is even more complicated.
Experiments in mice and human cells shed light on best way
to deliver nanoparticle therapy for cancer
